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AbstrAct 
Objective: To define the pattern of disease expression
and to gain better understanding in patients with juve-
nile onset systemic lupus erythematosus (SLE) in Por-
tugal.
Methods: The features of unselected patients with sys-
temic lupus erythematosus who had disease onset be-
fore the age of 18 years were retrospectively analysed
in three Portuguese centres with Pediatric Rheumato-
logy Clinic over a 24-year period (1987-2011). Demo-
graphic, clinical and laboratory manifestations, thera-
py and outcome were assessed. 
Results: A cohort of 56 patients with a mean age at di-
sease onset of 12.6±4.04 years (mean±1SD) (range, 1.0-
-17.0 years) and a mean period of follow-up of 5.5±5.4
years. Forty six (82.1%) patients were female. The most
common disease manifestations were musculoskeletal
(87.5%), mucocutaneous (80.3%) and haematological
abnormalities (75%). Lupus nephritis was diagnosed
in 46.4% of patients and consisted of glomerular ne -
phritis in all cases. Neuropsychiatric manifestations oc-
curred in 21.4% but severe central nervous system
complications were uncommon, as brain infarcts and
organic brain syndrome in 4 (7.1%) patients. Antinu-
clear antibodies and anti-double stranded DNA were
positive in most patients in (98.2% and 71.4% respec-
tively), as well as low C3 and/or C4 were observed fre-
quently (85.7%). Generally, most patients had a good
response to therapy as demonstrated by a significant
decreasing of SLEDAI score from disease presentation
to the last evaluation. The SLEDAI at diagnosis, the ma-
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ximum SLEDAI and the incidence of complications
were significantly higher in patients with neurolupus
and/or lupus nephritis. Therapy included oral steroids
(87.5%), hydroxychloroquine (85.7%), azathioprine
(55.4%), IV cyclophosphamide (28.6%) along with 
other drugs. Six (10.7%) patients were treated with ri-
tuximab. Long-term remission was achieved in 32%,
disease was active in 68%, adverse reactions to thera-
py occurred in 53.6% and complications/severe mani-
festations in 23.2%. Two patients died, being active di-
sease and severe infection the causes of death.
Conclusions: This study suggests that in our patients
the clinical and laboratory features observed were si-
milar to juvenile systemic lupus erythematosus patients
from other series. Clinical outcome was favourable in
the present study. Complications from therapy were
frequent. Objective: To define the pattern of disease ex-
pression and to gain better understanding in patients
with juvenile onset systemic lupus erythematosus (SLE)
in Portugal. 
Methods: The features of unselected patients with sys-
temic lupus erythematosus who had disease onset be-
fore the age of 18 years were retrospectively analysed
in three Portuguese centres with Pediatric Rheumato-
logy Clinic over a 24-year period (1987-2011). Demo-
graphic, clinical and laboratory manifestations, thera-
py and outcome were assessed. 
Results: A cohort of 56 patients with a mean age at di-
sease onset of 12.6±4.04 years (mean±1SD) (range, 1.0-
-17.0 years) and a mean period of follow-up of 5.5±5.4
years. Forty six (82.1%) patients were female. The most
common disease manifestations were musculoskeletal
(87.5%), mucocutaneous (80.3%) and haematological
abnormalities (75%). Lupus nephritis was diagnosed
in 46.4% of patients and consisted of glomerular ne -
phritis in all cases. Neuropsychiatric manifestations
occur red in 21.4% but severe central nervous system
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complications were uncommon, as brain infarcts and
organic brain syndrome in 4 (7.1%) patients. Antinu-
clear antibodies and anti-double stranded DNA were
positive in most patients in (98.2% and 71.4% res-
pectively), as well as low C3 and/or C4 were observed
frequently (85.7%). Generally, most patients had a
good response to therapy as demonstrated by a signi-
ficant decreasing of SLEDAI score from disease pre-
sentation to the last evaluation. The SLEDAI at diagno -
sis, the maximum SLEDAI and the incidence of com-
plications were significantly higher in patients with
neurolupus and/or lupus nephritis. Therapy included
oral steroids (87.5%), hydroxychloroquine (85.7%),
azathioprine (55.4%), IV cyclophosphamide (28.6%)
along with other drugs. Six (10.7%) patients were trea-
ted with rituximab. Long-term remission was achie-
ved in 32%, disease was active in 68%, adverse reac-
tions to therapy occurred in 53.6% and complica-
tions/severe manifestations in 23.2%. Two patients
died, being active disease and severe infection the cau-
ses of death.
Conclusions: This study suggests that in our patients
the clinical and laboratory features observed were si-
milar to juvenile systemic lupus erythematosus pa-
tients from other series. Clinical outcome was favou-
rable in the present study. Complications from thera-
py were frequent.
Keywords: Juvenile; Systemic Lupus Erythematosus.
introduction
Juvenile systemic lupus erythematosus (jSLE) is a chro-
nic multisystem autoimmune disease of unpredicted
course and prognosis1,2. It manifests with a wide spec-
trum of clinical and immunological abnormalities,
which range from skin rashes and oral ulcers to life-
threatening neurological, hematological and renal in-
volvement.2,3,4 Although SLE is most commonly diag-
nosed in women during the second to fourth decades
of life, disease onset can occur at any age. It is rare in
childhood, but in 15 to 20% of all SLE patients the
diagnosis is made for the first time before 16 years
old3,5 and, to our best knowledge, there is only one stu-
dy (published in 1994) that aims to demonstrate de-
mographic, clinical and laboratory characteristics and
outcome of SLE in Portuguese pediatric patients6.
Several investigators have reported that age at on-
set has a modifying effect on disease expression7. This
is important because examination of more homoge-
neous subsets, such as childhood onset patients, may
allow an earlier diagnosis, better treatment, and more
accurate prognosis. It has been noted that certain fea-
tures of SLE usually associated with severity, such as
nephritis or central nervous system dysfunction, are
more common in patients with childhood onset SLE
(cSLE)7.
The incidence of SLE varies according to each po-
pulation’s characteristics, such as patients’ age, gender,
ethnicity, and the period of time studied. Epidemiolo-
gic studies suggest that SLE occurrence differs among
different countries, and even among different areas of
the same country8,9. These differences are also observed
among population groups of the same race living in dif-
ferent parts of the world, suggesting that besides gene-
tic susceptibility, geographic and environmental fac-
tors are probably implicated in development of this
connective tissue disease9,10.
In this study, to better define the pattern of disease
expression in jSLE patients, we have retrospectively
analyzed the clinical and immunological features, treat-
ments, complications and outcome of 56 patients in
whom the first manifestations appeared in childhood
or adolescence.
PAtients And Methods
The present study reports a cohort of 56 SLE patients
with disease onset before the age of 18 year-old, that
were followed consecutively either as inpatients or out-
patients over a 24-year period (from January 1987 un-
til November 2011) in three different referral centers,
with different epidemiological characteristics and cul-
tures of its patients: 1) a private Rheumatology center
and a reference for pediatric rheumatologic patients
from different regions of the country, 2) a tertiary pe-
diatric hospital in the centre of Lisbon and 3) an hos-
pital in the suburban area of Lisbon, with an impor-
tant prevalence of immigrant patients (Amadora).
We considered cSLE when age onset was below 10
year-old.
All patients fulfilled at least four of the American
College of Rheumatology criteria for the classification
of SLE11,12.
We performed a retrospective review of the records
from patients diagnosed as jSLE. The data were retrie-
ved on a pre-designed protocol form. Information ga -
thered included patients’ age at onset, gender, ethnici-
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ty, disease duration (calculated from symptoms onset
to the end of the study or patients’ death), follow up
duration, different clinical features at presentation and
follow up, complications, therapy and outcome. La-
boratory data collected included hematological, renal
and immunological parameters consisting of comple-
te blood counts (leucopenia was considered for white
blood cell count (WBC) <4,000/mm3, anemia for he-
moglobin (Hb) < 11g/dL, lymphopenia for lymphocy-
tes <1,500/mm3, thrombocytopenia for platelets <150
× 103/mm3), serum creatinine, 24-hours urine pro-
tein excretion, antinuclear antibodies (ANA), double
stranded (ds) DNA antibodies, anti-SSA/Ro, anti-
-SSB/La, anti–Sm, anti-ribonucleoprotein (RNP), anti-
cardiolipin (aCL), anti-b2glycoprotein I (anti-b2GPI)
(IgG and IgM) antibodies and lupus anticoagulant
(LAC), the lowest levels of complement components 3
and 4 (C3 and C4) (low C3:<90mg/dl; low
C4:<20mg/dl) and the highest erythrocyte sedimenta-
tion rate (ESR) value (elevated ESR: >20mm at 1 hour).
Hemolytic anemia was considered when direct
Coombs’ test was positive.
Lupus nephritis or nephropathy was defined by the
presence of any of the following indicators: proteinu-
ria >0.5g/day, persistent cellular cast and/or hematu-
ria, decreased glomerular filtration rate, abnormalities
on the renal biopsy and end-stage renal disease (ESRD)
treated by dialysis or transplant.
Myositis was considered if confirmation of muscle
inflammation by muscular enzymes elevation and
magnetic resonance.
Pericarditis was considered in the presence of peri-
cardial pain and/or effusion and/or compatible elec-
trocardiogram abnormalities.
Neuropsychiatric symptoms were considered when
the patient with the established diagnosis of active jSLE
presented the following manifestations: psychiatric di-
sorders (anxiety and/or depression, psychosis, deli-
rium, paranoid features or hallucination, confirmed
by psychiatrist evaluation), moderate to severe heada-
che, ataxia, peripheral neuropathy, myopathy, chorea
or seizure not attributed to another causes, cerebro-
vascular accident (confirmed by computerized tomo-
graphy or magnetic resonance imaging) or other type
of cognitive disorder. Organic brain syndrome was
considered in the presence of altered mental function
with impaired orientation, memory or other cognitive
function or decreased psychomotor activity.
Data related to different treatment options, hospi-
talization and disease outcome were also gathered. The
outcome measures were: 1) remission (defined as long-
term (more than 6 months) absence of disease activi-
ty manifestations, including clinical features and la-
boratory indices), either on treatment or off treatment;
2) active disease on treatment and its degree of activi-
ty according to the last SLEDAI score (mild if ≤3, mo-
derate if >3 and ≤12 and severe if >12); 3) complica-
tions (secondary to the underlying disease or as thera-
py adverse effects) and 4) death. Diagnosis of anti-
phospholipid syndrome had to meet diagnostic
criteria13. Only severe infection was considered as com-
plication/severe manifestation and it was defined as
any infection that resulted in hospitalization, in delay
in an existing hospitalization and/or was life threate-
ning and/or caused death. The clinical activity was as-
sessed by the Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) score at the time of initial pre-
sentation, during and after treatment14,15. The maxi-
mum SLEDAI during follow-up was calculated retros-
pectively for all patients from medical record. We in-
cluded the latest SLEDAI, documented in medical re-
cord, for those who defaulted or died before
concluding the study in November 2011.
Statistical analysis of the data was performed using
SPSS® 19.0 (SPSS Inc., Chicago, Illnois, EUA). Conti-
nuous data were expressed as mean T ± standard de-
viation (SD) or median and range or interquartile ran-
ge, and categorical variables as percentages. For con-
tinuous variables, mean values were compared using
T-student test or Mann-Whitney test depending on
normality distribution of results. Categorical variables
were analyzed using Chi-square test or Fisher exact
test, as needed.
results
Fifty-six patients, 91.1% Caucasian, 82.1% female
with a ratio female/male of 4.6/1 and a mean (±SD) age
at diagnosis of 12.6±4.04 years (range, 1.0-17.0 years),
were enrolled. Mean (±SD) period of follow-up was
5.5±5.4 years (range, 0-288 months). Patient charac-
teristics are shown in Table I. The delay on diagnosis
was on average 12.4±19.0 months (extremes of 0.5
and 84 months). 23.2% had relatives with autoimmu-
ne diseases, four (7.1%) with SLE, and there was a cou-
ple of monozygotic twin sisters concordant for jSLE.
26.8% had some comorbidities; from them we high-
light: sickle cell disease, Down syndrome, asthma, Gra-
ves disease, hepatic hemangioma, vitiligo and pituita-
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ry hypoplasia.
The presenting symptoms at diagnosis are summa-
rized in Table II. Musculoskeletal, mucocutaneous and
hematological involvement were the major clinical ma-
nifestations. The cumulative frequencies of systemic
involvement are presented in Table III, being articular
involvement the most prevalent (85.7%). General
symptoms (fever and/or asthenia and/or weigh lost)
were present in 42 (75%) patients. Malar rash and Ray-
naud’s phenomenon were the commonest mucocuta-
neous features. On the other hand, discoid lupus oc-
curred in only one patient.
Hematologic abnormalities were found in 75% pa-
tients. Lymphopenia was the commonest and it was
identified in 80.8% patients. Anemia at any time of the
disease occurred in 48.2% patients, but only 25% had
confirmed hemolytic anemia. Thrombocytopenia was
seen in 37.5%, and occurred around the time of diag-
nosis in nearly half of the patients; however, in six of
them thrombocytopenia predated the definite diagno-
sis of jSLE by months and even years (mean 33,5±28.5
months; extremes of 5 months and 7 years).
Twenty-six (46.4%) had renal involvement and con-
sisted of glomerular nephritis in all cases. Twenty of
them (76.9%) underwent renal biopsy. Biopsies were
assigned to WHO classes as follows: minimal change
(class I) in 1 (5%) patient; mesangial glomerulone -
phritis (class II) in 5 (25%); focal segmental prolifera-
tive glomerulonephritis (class III) in 4 (20%), diffuse
proliferative glomerulonephritis (class IV) in 9 (45%)
and membranous glomerulonephritis in 1 (5%). No
isolated interstitial nephritis was seen.
Pericarditis was present in 25% and it was recur-
rent in two patients (one patient had four different epi-
sodes).
Neuropsychiatric systemic lupus erythematosus
(NPSLE) occurred in 21.4% of patients, being lupus
headache the commonest manifestation. Its severe ma-
nifestations, as seizure, cerebrovascular accident and
organic brain syndrome were rare complications.
Respiratory system and gastrointestinal involvement
were rare in our cohort of patients (Table III).
Immunological features and other laboratory fin-
dings are discriminated in Tables IV and V.
Most patients received oral corticosteroid (87.5%)
and chloroquine/hydroxychloroquine (85.7%) for
treatment. Twenty-four (42.9%) were treated with in-
travenous (IV) pulse methylprednisolone. 69.6% pa-
tients were given immunosuppressive therapy with
azathioprine in 55.4%, cyclophosphamide in 28.6%,
mycophenolate mofetil in 14.3%, methotrexate in
14.3% and cyclosporine in 3.6%. Six patients were
treated, with rituximab (four patients with neurolu-
pus, one of them complicated by severe epilepsy and
cerebrovascular infarct; five patients with severe he-
matological involvement and four of them with si-
tAble i. MAin ePideMiologic feAtures of
PAtients diAgnosed with jsle, 1987-2011
Characteristic
Total no. of patients 56
Female/male (no.) 46/10
Female (%) 82.1
Age, yr* at symptom onset 12.6 ± 4.04; 13,5 (1 – 17)
Delay to diagnosis, months† 12.4 ± 19.0; 4 (0.5 – 84)
Follow-up from disease 5.5 ± 5.4; 4 (0-24)
diagnosis, yr*
Abbreviations: IQR = interquartile range
*MeanT±SD; median (IQR)
†Delay to diagnosis from the onset of symptoms to the time of
diagnosis of SLE. Mean T±SD; Median (IQR)
tAble ii. Presenting syMPtoMs
Patients (Total = 56)
Category n (%)
Arthritis/Arthralgia 23 (41.1)
Myalgia 1 (1.8)
Malar rash 6 (10.7)
Photosensitivity 1 (1.8)
Maculopapular rash 1 (1.8)
Hematological disorder 8 (14.3)
Thrombocytopenia 7 (12.5)
Anemia 1 (1.8)
Raynaud’s phenomenon 2 (3.6)
Skin vasculitis 2 (3.6)
Discoid rash 1 (1.8)
Subcutaneous nodules 1 (1.8)
Weight loss 2 (3.6)
Fever 5 (8.9)
Neurological disorder 
(intense headache) 1 (1.8)
Serositis (Pericarditis) 1 (1.8)
Lymphadenopathy 1 (1.8)
Nephrotic syndrome 1 (1.8)
Vascular thrombosis 1 (1.8)
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multaneous renal involvement, all of them refractory
to previous immunosuppressive therapy). Treatment
also included IV immunoglobulin in 17.9%, intra-ar-
ticular steroids in one, oral anticoagulants in 7.1% and
as general maintenance therapy: NSAIDS, anti-hyper-
tensive agents, calcium carbonate and Vitamin D.
Mean (±SD) duration of steroid therapy was 47.6±59
months (range, <1 – 250 months/20.8 years) and for
immunosuppressive agents it was 42.9±52.9 months
(range, <1 – 190 months/15.8 years).
Disease activity was evaluated by SLEDAI and its
average at the time of diagnosis was 11.0±9.1 (range,
0–44). Analyzing the maximum SLEDAI during fol-
low up for each patient, its average was 14.5±10.6
(range, 0–47) and in the last evaluation it was 2.6±3.6
(range, 0–16).
Improvement of clinical features, reflected by a de-
creasing from the maximum to the final SLEDAI, was
noted in 48/50 (96%) patients. Clinical, biological and
immunological complete remission for more than 6
months was obtained in 16/50 (32%) patients (wi thout
treatment: 9 (18%) patients). Disease was active in
34/50 (68%) and two (3.6%) patients died (Table VI).
The causes of death were: 1) Sepsis and active SLE due
to treatment discontinuation in one patient; 2) sudden
*Miositis confirmed by muscular enzymes elevation and/or 
magnetic resonance
**Anemia (Hb<12g/dl); Thrombocytopenia
(Platelets<150.000/mm3); Leucopenia (Leucocytes<4.000/mm3);
Lymphopenia (Lymphocytes<1500/ mm3)
***Persistent proteinuria >0.5g/24hours or cellular casts (granular,
WBC and/or hematuria)
tAble iii. cuMulAtive frequencies of systeMic
involveMent in our cohort
Clinical features Patients (Total = 56)
n (%)
Musculoskeletal 49 (87.5)
Articular (arthritis and/or 48 (85.7)
arthralgia)
Myalgia / Miositis* 6 (10.7)/3
(5.4) 
Serositis 16 (28.6)
Pericarditis 14 (25)
Pleuritis 7 (12.5)
Peritonitis 2 (3.6)
Mucocutaneous 45 (80.3)
Malar rash 30 (53.6)
Discoid rash 1 (1.8)
Skin vasculitis 10 (17.9)
Urticariform vasculitis 1 (1.8)
Mucocutaneous hemorrhage 11 (19.6)
Photosensitivity 14 (25)
Livedo reticularis 13 (23.2)
Raynaud’s phenomenon 15 (26.8)
Mechanic hands 1 (1.8)
Oral and/or nasal ulcers 14 (25)
Enantema 15 (26.8)
Hematological disorder** 42 (75)
Anemia 27 (48.2)
Thrombocytopenia 21 (37.5)
Leucopenia 29 (51.8)
Lymphopenia 42 (80.8)
Renal disease*** 26 (46.4)
Neuropsychiatric disorder 12 (21.4)
Lupus headache 7 (12.5)
Seizure 3 (5.4)
Psychosis 3 (5.4)
Organic brain syndrome 4 (7.1)
Cerebrovascular accident(s) 4 (7.1)
Ataxia 1 (1.8)
Other psychiatric symptoms 7 (12.5)
Miscellaneous
Subcutaneous nodules 6 (10.7)
Weight loss 17 (30.4)
Astenia 28 (50)
Fever 31 (55.4)
Alopecia 3 (5.4)
Hair loss 18 (32.1)
Lymphadenopathy 8 (14.3)
continues on the next column
tAble iii. continuAtion
Patients (Total = 56)
Clinical features n (%)
Hepatomegaly 6 (10.7)
Generalized edema 1 (1.8)
Secondary amenorrhea 2 (3.6)
Bilateral red eyes 3 (5.4)
Cardiovascular 23 (41)
Pericarditis 14 (25)
Vascular thrombosis 5 (8.9)
Libman-Sacks Endocarditis 1 (1.8)
Myocardium infarct 1 (1.8)
Cardiac failure 2 (3.6)
Interstitial lung disease 1 (1.8)
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sis may be considered as a complication associated
with corticosteroids and/or a rare manifestation of
jSLE, and it was observed in one patient. Besides renal
involvement and NPSLE, complications were more fre-
quent in patients with African-ancestry, anemia, leu-
copenia and low C3 (Table VIII). Treatment adverse
effects occurred in 50%, being visceral obesity the most
prevalent (Table VII).
Contrary to expected, age below 10 year-old was
not statistically associated with renal involvement,
NPSLE, higher incidence of complications or higher
maximum SLEDAI (Table VIII).
Considering correlations with patients’ ethnicity, re-
nal or neuropsychiatric disorders were not more fre-
quent in African-ancestry patients, but they had more
complications (75% vs 28%, p=0.05) and a higher in-
cidence of positive LAC (60% vs 14%, p=0.01) (Table
VIII).
Comparing clinical and laboratory features in our
cohort of patients, with and without renal involve-
ment, showed that lupus nephritis was notably asso-
ciated with malar rash, lower WBC count, higher ESR,
lower Hb and C3 (Table VIII). From all immunologi-
cal tests, only anti-dsDNA antibodies were significan-
tly associated with renal disease. Also the incidence of
complications was higher in patients with lupus ne -
phritis (Table VIII). As we would expect, it was obser-
ved a tendency for arterial hypertension in patients
with nephritis (16% vs 3.6%), despite a not statisti-
cally significant association being demonstrable, pro-
bably because of the cohort’s dimension.
Neuropsychiatric manifestations were associated
with lower lymphocytes count but not with lower
WBC count, Hb or hypocomplementemia, contrarily
to the observed with lupus nephritis. On the other
hand, the incidence of complications, anti-Sm, anti-
-SSA and anti-RNP antibodies were significantly 
hi gher in patients with NPSLE. However antiphos-
tAble iv. frequency of PAtients with Positive
iMMunologicAl tests
Patients (Total = 56)
Immunological test (%)
ANA 98.2
Anti-DNAds 71.4
Anti-Sm 12.5
Anti-RNP 21.4
Anti-SSA (RO) 23.2
Anti-SSB (La) 3.6
Anticardiolipin IgM/IgG 16
Anti-β2glycoprotein I 16
Low serum C3 71.4
Low serum C4 78.6
Abbreviations: ANA, antinuclear antibodies; Anti-Sm, 
anti-Smith, ESR, erythrocyte sedimentation rate
tAble vi. diseAse outcoMe in jsle PAtients
Patients (Total = 56)
Outcome n (%)
Remission on treatment 7/50 (14)
Remission, therapy discontinued 9/50 (18)
Active disease 34/50 (68)
Lost follow up 4 (7.1)
Death 2 (3.6)
Abbreviations: ESR, erythrocyte sedimentation rate; RV, reference
value; *minimum absolute value; **maximum absolute value
tAble v. generAl lAborAtory findings
Laboratory findings Mean T ± SD IQR
Hemoglobin (g/dl)* 10.2±2.4 2.8-14.7
Platelets (x103/mm3)* 159±108 2-459
White blood cell count 
(/mm3)* 3,794±1,604 1,400-10,600 
Lymphocytes (/mm3)* 1,037±703 100-4,028
C3 (mg/dl)* (RV: 90-180) 67.9±36.5 8-230 
C4 (mg/dl)* (RV: 20-50) 11.9±13.3 0.05-86 
Elevated ESR (>20mm/ 74±40.9 5-155 
1st hour)**
C-reactive protein 
(mg/dl)** 4.5±7.2 0.01-36.2
Creatinine (mg/dl)** 0.91±0.3 0.48-2.1 
Proteinuria (g/24hours)** 0.861±1.215 0.07-6
cardiac arrest secondary to ventricular fibrillation in a
patient with sickle cell disease and severe cardiac com-
plications inherent to SLE (Libman-sacks endocardi-
tis; bacterial endocarditis, myocardium infarct) during
recovery from pneumonia. Both patients who died had
frequently an uncontrollable or progressive multisys-
temic disease.
Complications and/or severe manifestations occur-
red in 23.2%. Infection was the leading complication
during treatment of jSLE (Table VII). Avascular necro-
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pholipid antibodies were not statistically correlated,
contrarily to the expected (Table VIII).
Anti-SSA antibodies were more frequent in patients
with livedo reticularis, but the second was not statis-
tically associated with antiphospholipid antibodies.
On the other hand, anti-SSB antibodies were more fre-
quent in patients with skin vasculitis (20% vs 0%,
p=0.002) (Table VIII).
The mean SLEDAI at SLE diagnosis and the 
mean maximum SLEDAI were significantly higher in
patients with lupus nephritis and neurolupus (Table
VIII).
discussion
There have been several studies dealing with jSLE and
their results suggested that age at onset modifies di-
sease’s expression in terms of clinical presentation, 
pattern of organ involvement, and serological fin-
dings6,7,16-23. However, the true prevalence of jSLE
among the SLE population is unknown7. One of the
reasons is that there is not a strict definition of jSLE.
The most often used cut off ages are 14 or 16 years at
onset of disease18–20 or at diagnosis21. However, several
studies use a higher or lower cut off age. In our study
we considered the onset age lower than 18 years for
our cohort of jSLE, considering that in Portugal pe-
diatric health care centers receive patients from 0 to
18 year-old.
A potential limitation of this study was the inclusion
of a heterogeneous group of patients from different 
ethnic backgrounds. Other important limitations were
the retrospective review and the small sample of pa-
tients, which might have interfered with the results
from statistical correlations. However, this is a true re-
presentation of the general pediatric population living
in Lisbon (centre and suburbs).
The female to male ratio in adult-onset SLE (aSLE)
is generally found to be slightly more than 10:1.724,25.
A higher proportion of male patients is often reported
in jSLE in some series17,21,22 but not in others7. In our
cohort, male represented 17.9% of the cases with a fe-
male to male ratio of 4.6:1, which is the common in-
cidence reported for cSLE26.
Generally, about 10% of SLE patients have familial
SLE25, and it was corroborated in our study.
This group of patients had clinical presentation, de-
mographic and laboratory data comparable to previous
studies about jSLE, including the Portuguese cohorts
of juvenile patients described by Costa MM et al and the
adult patients described by Santos MJ et al3,6,7,16,17,19-23,27.
Similar to those studies, hematological and renal in-
volvement were between the most common manifes-
tations6,16,17,19,22,23. However, contrarily to the cohort of
childhood-onset (<16 years) described by Pusongchai
et al, and comparable to other studies including adult
patients, mucocutaneous and articular features were
the commonest manifestations in our patients24,25,28.
Perhaps that’s because our cohort included not only
children but also adolescents (<18 year-old), whose
clinical presentation might be probably nearest to the
aSLE.
The onset of SLE is rare before the age of 5 year-
tAble vii. coMPlicAtions And/or severe 
MAnifestAtions develoPed during follow 
uP of the jsle PAtients
Patients (Total = 56)
Outcome n (%)
Infection 6 (10.7)
Pneumonia 2 (3.6)
Sepsis 1 (1.8)
Bacterial endocarditis 1 (1.8)
Cellulite 3 (5.3)
Cognitive impairment 4 (7.1)
ESRD 2 (3.6)
On conservative therapy 1 (1.8)
On dialysis 1 (1.8)
Vascular thrombosis 5 (8.9)
Cerebrovascular 4 (7.1)
Cerebral hemorrhage 2 (3.6)
Epilepsy 3 (5.3)
Cardiac failure 2 (3.6)
Myocardium infarct 1 (1.8)
Arterial hypertension 5 (8.9)
Antiphospholipid syndrome 2 (3.6)
Macrophage activation syndrome 2 (3.6)
Avascular necrosis  1 (1.8)
Gastrointestinal tract bleeding 1 (1.8)
Treatment adverse effects 28 (50)
Osteoporosis* 5 (8.9)
Visceral obesity 25 (44.6)
Growth delay 3 (5.3)
Ophthalmological complications 6 (10.7)
Cataract 4 (7.1)
Hydroxychloroquine 2 (3.6)
maculopathy
Abbreviations: ESRD, end stage renal disease
*Confirmation with DEXA
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tAble viii. stAtisticAl correlAtions found with luPus nePhritis, nPsle And other 
significAnt stAtisticAl correlAtions 
Statistical correlations with Lupus Nephritis n= 56 p
Age, yr* at symptom onset 12.8±3.8 vs 12.5±4.3 0.730
Malar rash 73% vs 36.7% 0.006
White blood cell count (minimum absolute count)* 3205±1048 vs 4306±1831 0.009
Lymphocytes (minimum absolute count)* 869±467 vs 1193±846 0.097
Erythrocyte sedimentation rate (maximum value)* 92.7±36.6 vs 57.8±37.9 0.001
Hemoglobin (minimum absolute concentration)* 9,5±2.4 vs 10.8±2.2 0.039
Low C3 (<90mg/dl) 92.3% vs 53.3% 0.001
Low C4 (<20mg/dl) 88.5% vs 70% 0.093
Low C3 and C4 84.6% vs 46.7% 0.003
Anti-DNAds 92.3% vs 53.3% 0.001
Anti-SSA 26.9% vs 20% 0.541
Anti-SSB 3.8% vs 3.3% 0.918
Anti-Sm 57.1% vs 44.9% 0.543
Anti-RNP 19.2% vs 23.3% 0.709
General complications / severe manifestations 48% vs 17.2% 0.015
Antiphospholipid syndrome 8% vs 0% 0.127
Pericarditis 30.8% vs 20% 0.353
Arterial hypertension 16% vs 3.6% 0.122
SLEDAI at disease onset* 15.6±9.8 vs 7.1±6.3 0.000
Maximum SLEDAI* 21.5±10.4 vs 9.2±7.1 0.000
Statistical correlations with NPSLE n= 56 p
Age, yr* at symptom onset 10.9±5.2 vs 13.1±3.6 0.095
White blood cell count (minimum absolute count)* 3148±781 vs 3971±1729 0.116
Lymphocytes (minimum absolute count)* 744± vs 1125±766 0.014
Erythrocyte sedimentation rate (maximum value)* 75.6±44.2 vs 73.6±40.5 0.881
Hemoglobin (minimum absolute concentration)* 9.7±2.3 vs 10.3±2.4 0.419
Low C3 (<90mg/dl) 75% vs 70.5% 0.757
Low C4 (<20mg/dl) 66.7% vs 81.8% 0.257
Anti-DNAds 91.7% vs 65.9% 0.080
Anti-SSA 50% vs 15.9% 0.013
Anti-SSB 8.3% vs 2.3% 0.316
Anti-Sm 57.1% vs 16.3% 0.014
Anti-RNP 41.7% vs 15.9% 0.054
Lupus anticoagulant 16.7% vs 18.6% 0.878
aCL 16.7% vs 16.3% 0.974
Anti-ß2GP1 8.3% vs 18.6% 0.395
General complications 72.7% vs 20.9% 0.001
Antiphospholipid syndrome 9.1% vs 2.4% 0.299
SLEDAI at disease onset* 18.1±12.2 vs 9.1±7.2 0.013
Maximum SLEDAI * 25.6±12.3 vs 11.6±7.9 0.001
Another statistical correlations n= 56 p
Leucopenia (<4000/mm3) # Complications 76.5% vs 40.5% 0.014
Lymphopenia (<1500/ mm3)# maximum SLEDAI 17.0±10.7 vs 7.5±6.3 0.003
Low C3 (<90mg/dl) # Complications 94.1% vs 62.1% 0.015
continues on the next column
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-old7. In this cohort, one patient presented the first cli-
nical manifestations of SLE at the age of 12 months. Ac-
tually, it is known that the age at disease onset has an
important impact on the clinical course and outcome
of SLE. Previous reports comparing childhood with
adult SLE reported that certain features of SLE usual-
ly associated with severity, such as nephritis or central
nervous system (CNS) dysfunction, are commonest in
patients with cSLE. Therefore, it is assumed that cSLE
is associated to a more severe disease course and wor-
se prognosis3,7. Although renal and CNS involvement
were not statistically associated with age onset below
10 year-old, actually the younger patient in our study
had a severe disease course, with renal involvement
and severe neurolupus complicated by cerebrovascu-
lar infarct26. However, we didn’t find a significant sta-
tistical association between age onset below 10 year-
-old and maximum SLEDAI or the occurrence of more
complications/severe manifestations. In this way, the
precise differences between child and adult-onset SLE
in the prevalence of its manifestations may be still de-
bated3. A meta-analysis conducted by Livingston B et al
found that malar rash, ulcers/mucocutaneous invol-
vement, renal disease, neuropsychiatric manifesta-
tions, thrombocytopenia, hemolytic anemia, fever and
lymphadenopathy were more common in cSLE. On
the other hand, Raynaud’s phenomenon, pleuritis, dis-
coid rash and sicca symptoms were more common in
aSLE3. Hematological abnormalities, specifically he-
molytic anemia and thrombocytopenia, fever and
lymphadenopathy were more frequent in our cohort
when compared to other series with a predominance
of adult patients, as it was also reported by Font J et
al.7,24,25. Conversely, discoid lesions were really more
frequent in series of aSLE (our cohort had only one
isolated case), but no significant differences were seen
considering frequencies of Raynaud’s and pleuritis7,24,25.
Renal involvement is one of the most important pre-
dictors of a poor outcome. Its manifestations are va-
riable, ranging from mild asymptomatic proteinuria to
rapidly progressive glomerulonephritis leading to end-
-stage renal disease (ESRD)5, which was observed in
two patients in our study, despite their adequate treat-
ment. Class IV nephritis was the most frequent class
documented in our cohort, which is in agreement with
most of the previous reports28. This is comparable to
other studies from United States29 and Canada30, but
the frequency was lower than it was seen in cohorts
from Iran28 or Korea31. Aggressive treatment of lupus
nephritis, particularly class IV, have been recommen-
ded to prevent disease progression; the low incidence
of ESRD in the present study may reflect the adequa-
te and prompt management of active renal disease in
the three centers.
In our series, comparison of clinical and laboratory
features of SLE patients with and without renal invol-
vement showed that lupus nephritis was significantly
associated with activity markers of autoimmunity, as
moderate to severe anemia and leucopenia and eleva-
ted ESRD. Anti-dsDNA antibodies and lower C3 were
also associated with renal disease, as expected (Table
VIII). A comparative European study of two groups of
SLE patients with and without nephritis showed that
patients with renal involvement suffered more com-
monly from malar rash, pericarditis, arterial hyper-
tension and antiphospholipid syndrome32. Contrarily
to this and other studies, lupus nephritis was not as-
sociated with pericarditis, arterial hypertension or an-
tiphospholipid syndrome in our study, but effectively,
the statistical association with malar rash was verified
(Table VIII).
The prevalence of neuropsychiatric manifestations
tAble viii. continuAtion 
Statistical correlations with Lupus Nephritis n= 56 p
Anti-DNAds # Malar rash 83.3% vs 57.7% 0.034
Anti-SSA # Livedo reticularis 46.1% vs 16.3% 0.025
Anti-SSB # Skin vasculitis 20% vs 0% 0.002
African-descendants # lupus nephritis 40% vs 47% 0.763
# NPSLE 40% vs 19.6% 0.289
# Complications 75% vs 28% 0.051
# Lupus anticoagulant 60% vs 14% 0.011
Legend: *MeanT±SD; NPSLE – neuropsychiatric systemic lupus erythematosus
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in SLE patients varies widely among different series
depending on inclusion criteria and ethnic origin.
NPSLE have been reported to occur in 22–43% pe-
diatric SLE patients32. In our study the frequency of
neuropsychiatric manifestations was at the lower end
of the margin (21.4%). Probably, methodology diffe-
rences are responsible for this discrepancy between
studies. Cognitive disorder is diagnosed by cognitive
complaints or objective cognitive dysfunction evalua-
ted by standardized neuropsychological tests33, which
were not routinely performed in our patients. Other
neuropsychiatric manifestations such as peripheral
neuropathy or psychiatric disorders may also have not
been documented without a prospective evaluation,
which could explain its lower incidence in our cohort.
Several previous studies showed that neuropsychiatric
manifestations are associated with antiphospholipid
antibodies, especially IgG aCL and LAC33-35. Our pa-
tients with neurolupus didn’t show such association,
but revealed higher frequencies of severe lymphopenia,
anti-Sm, anti-RNP and anti-SSA antibodies than did
the patients without neuropsychiatric manifestations
(Table VIII).
The mean SLEDAI at SLE diagnosis, the mean ma-
ximum SLEDAI and the incidence of complications
were markedly higher in patients with lupus nephritis
and neurolupus, as observed in other studies (Table
VIII)27.
Comparison of the autoantibodies profile showed
that ANA and anti-dsDNA incidences were similar to
the majority of the studies1,4,7,23-25,27. However, anti-RNP,
anti-Sm, anti-SSA and anti-SSB antibodies were found
to have a lower incidence in our cohort, especially tho-
se concerning aSLE1,7,23-25,27. We are unable to explain
these immunologic findings, but it may be due to in-
ter-ethnic variation owing to genetic differences. Age
group could also assign this difference, as the majori-
ty of the other studies have predominantly adult pa-
tients. However, Font J et al reported the presentation
and the clinical course of SLE in a series of 430 pa-
tients depending on their age at disease onset and no
significant differences between cSLE and aSLE, except
for aCL antibodies, were found among immunological
tests7.
ANA are present in virtually all patients with SLE,
so much so that the diagnosis is seriously in doubt in
their absence; although clinically exceptional, most se-
ries present a patient with negative ANA, as our co-
hort. It was a 16-year-old female patient who presen-
ted with fever, asthenia, polyarthritis, pericarditis,
lymphadenopathy, hepatomegaly and lupus nephritis
confirmed by renal biopsy.
The prevalence of antiphospholipid antibodies in
SLE is about 20–60%,13 but in our cohort its inciden-
ce was lower for both aCL and anti-ß2GP1 antibodies
(16.4%). In addition, and contrarily to several other se-
ries, the frequency of neuropsychiatric disorders or
vascular thrombosis was not higher in patients with
positive aCL or anti-ß2GP1 antibodies and there was
no association between anti-ß2GP1 antibodies and
kidney disease (p=0.506) (Table VIII).
Pediatric SLE management is based on results from
small pediatric series, clinical experience and large ran-
domized controlled trials in adults. As a result of the
shortage of clinical controlled trials in children, treat-
ment protocols vary between different centers23. How -
ever, prognosis for jSLE has improved dramatically
over the last 20 years attributable to early diagnosis
and improved anti-inflammatory therapy5. It is of note
that therapy given to children in our study was simi-
lar to that carried out in patients from aSLE series, ex-
cept for a more common use of azathioprine in
ours7,23,25,27. Rituximab has been used as an adjunctive
therapy with good results in aSLE patients with seve-
re disease and refractory to traditional immunosup-
pressive drugs. However, studies demonstrating its sa-
fety profile and optimal regimen in children are requi-
red23,36,37. In this study, the authors report clinical ex-
perience on rituximab as an adjunctive therapy in six
jSLE patients. It is likely that it has contributed to the
good outcome of almost all these patients, reflected by
a significant decrease in SLEDAI score in the six pa-
tients. Nevertheless, renal function of one patient who
developed ESRD did not improve despite treatment
with this adjunctive agent.
Several agents used in jSLE therapy may produce
severe complications, especially corticosteroids rela-
ted adverse effects or gonadal toxicity and infections
from cyclophosphamide. Infection remains the most
common cause of morbidity and mortality in children
and adults with SLE38, as it was observed in our co-
hort. Other common causes of morbidity in our pa-
tients were the ophthalmologic complications, inclu-
ding cataract as a common side effect of corticosteroids
and chloroquine/hydroxychloroquine maculopathy,
the last one observed in two patients from our cohort
despite bi-annual retinal examination. No significant
differences were detected between other series con-
cerning side effects or drug toxicity.
Active disease and severe infection were the causes
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of death in our cohort. As infections in SLE are often
due to or influenced by the therapy employed, a ba-
lance between benefits and side effects should be con-
sidered very carefully when selecting treatment to con-
trol jSLE.
The most severe manifestations, lupus nephritis and
NPSLE, are associated with increased morbidity and
mortality and poor long-term outcome39, which was
corroborated by our results, revealing a significant 
higher maximum SLEDAI score in these groups of pa-
tients (Table VIII).
It is known that the clinical course of SLE may be
different in different ethnic groups. For example, the-
re is more renal disease in Asian than Caucasian pa-
tients, whereas African-American acquire more renal
damage than Asians3. In fact, recent studies demons-
trated that African-American patients are at increased
risk for developing severe renal, hematologic and CNS
involvement, with a poor long-term outcome, compa-
red to Caucasian children40. In our cohort there were
five African-ancestry children and their ethnicity was,
indeed, associated with an higher incidence of com-
plications/severe manifestations and, actually, one of
them died, although it was not associated with higher
SLEDAI scores.
Finally, although the disease’s complete remission
that was observed in 32% of our patients and the ex-
traordinary improvement of clinical features, with a
decreasing from the maximum to the final SLEDAI in
96% of the patients, we cannot assume that the present
study demonstrated a good clinical outcome of our
jSLE patients, considering the high rate of complica-
tions and/or severe manifestations (23.2% of patients)
and the occurrence of two deaths in a mean period of
follow-up of 5.5±5.4 years.
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